Unknown

Dataset Information

0

In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses.


ABSTRACT: Tumor acidity is the key metabolic feature promoting cancer progression and is modulated by pH regulators on a cancer cell's surface that pump out excess protons/lactic acid for cancer cell survival. Neutralizing tumor acidity improves the therapeutic efficacy of current treatments including immunotherapies. Vacuolar-ATPase (V-ATPase) proton pumps encompass unique plasma membrane-associated subunit isoforms, making this molecule an important target for anticancer therapy. Here, we examined the in vivo therapeutic efficacy of an antibody (a2v-mAB) targeting specific V-ATPase-'V0a2' surface isoform in controlling ovarian tumor growth. In vitro a2v-mAb treatment inhibited the proton pump activity in ovarian cancer (OVCA) cells. In vivo intraperitoneal a2v-mAb treatment drastically delayed ovarian tumor growth with no measurable in vivo toxicity in a transplant tumor model. To explore the possible mechanism causing delayed tumor growth, histochemical analysis of the a2v-mAb-treated tumor tissues displayed high immune cell infiltration (M1-macrophages, neutrophils, CD103+ cells, and NK cells) and an enhanced antitumor response (iNOS, IFN-y, IL-1?) compared to control. There was marked decrease in CA-125-positive cancer cells and an enhanced active caspase-3 expression in a2v-mAb-treated tumors. RNA-seq analysis of a2v-mAb tumor tissues further revealed upregulation of apoptosis-related and toll-like receptor pathway-related genes. Indirect coculture of a2v-mAb-treated OVCA cells with human PBMCs in an unbuffered medium led to an enhanced gene expression of antitumor molecules IFN-y, IL-17, and IL-12-A in PBMCs, further validating the in vivo antitumor responses. In conclusion, V-ATPase inhibition using a monoclonal antibody directed against the V0a2 isoform increases antitumor immune responses and could therefore constitute an effective treatment strategy in OVCA.

SUBMITTER: Kulshrestha A 

PROVIDER: S-EPMC7530789 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses.

Kulshrestha Arpita A   Katara Gajendra K GK   Ibrahim Safaa A SA   Riehl Valerie E VE   Schneiderman Sylvia S   Bilal Mahmood M   Young Alexandria N AN   Levine Shayna S   Fleetwood Sara S   Dolan James J   Gilman-Sachs Alice A   Beaman Kenneth D KD  

Molecular oncology 20200910 10


Tumor acidity is the key metabolic feature promoting cancer progression and is modulated by pH regulators on a cancer cell's surface that pump out excess protons/lactic acid for cancer cell survival. Neutralizing tumor acidity improves the therapeutic efficacy of current treatments including immunotherapies. Vacuolar-ATPase (V-ATPase) proton pumps encompass unique plasma membrane-associated subunit isoforms, making this molecule an important target for anticancer therapy. Here, we examined the i  ...[more]

Similar Datasets

| S-EPMC3484462 | biostudies-literature
| S-EPMC3659395 | biostudies-literature
| S-EPMC8553560 | biostudies-literature
| S-EPMC2742361 | biostudies-literature
| S-EPMC3394719 | biostudies-literature
| S-EPMC9357105 | biostudies-literature
| S-EPMC9171637 | biostudies-literature
| S-EPMC6680144 | biostudies-literature
| S-EPMC7054725 | biostudies-literature
| S-EPMC4019904 | biostudies-other